ReviewMetabolic brain disease2026
The metabolic roots of memory loss: interlinking the Diabetes-Alzheimer's hypothesis.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) and Alzheimer’s disease (AD) are two of the most widely recognized as prevalent conditions affecting the global elderly population. AD is primarily characterized by the accumulation of misfolded proteins, including amyloid-β (Aβ) plaques and hyperphosphorylated tau tangles that lead to progressive neuronal dysfunction in the brain. Conversely, DM is marked by impaired insulin signaling, resulting in reduced glucose uptake, disrupted energy metabolism, and altered hepatic glucose-to-lipid conversion. Despite their distinct clinical manifestations, growing evidence suggests that DM and AD share multiple overlapping molecular and cellular mechanisms. These include impaired glucose and lipid metabolism, mitochondrial dysfunction, oxidative stress, chronic inflammation, and excessive production of Aβ, all of which contribute to neurodegeneration and cognitive decline. Epidemiological studies further indicate that individuals with Type 2 DM are at a markedly higher risk of developing AD, highlighting the significance of metabolic dysfunction in neurodegenerative processes. Environmental and lifestyle factors such as diet, physical inactivity, and exposure to metabolic stressors may further amplify this bidirectional association. This review comprehensively explores the shared pathological mechanisms linking DM and AD, integrating insights from epidemiological data, mechanistic research, and experimental animal studies to elucidate how metabolic dysregulation underpins neurodegeneration, thereby offering a framework for identifying potential therapeutic strategies targeting both disorders.
Indexed as
Identifiers
41863579What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.